Jorge E. Cortes, MD

Jorge E. Cortes, MD, discusses the safety profile of olutasidenib for the treatment of patients with relapsed/refractory acute myeloid leukemia that harbor an IDH1 mutation.

Jorge E. Cortes, MD, provides an overview of the background and findings of the phase 1/2 Study 2102-HEM-101 of olutasidenib in patients with relapsed/refractory IDH1-mutated acute myeloid leukemia.

Jorge E. Cortes, MD, discusses the current therapies available to treat patients with chronic myeloid leukemia and how to choose between them when there is similar efficacy.

Jorge E. Cortes, MD, discusses the 5-year overall survival results of CPX-351 versus 7+3 in patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Jorge E. Cortes, MD, explains how ruxolitinib is used to treat various myeloproliferative neoplasms and which patients require other therapies.